Cognition Therapeutics (CGTX) Share-based Compensation (2020 - 2026)
Cognition Therapeutics (CGTX) reported Share-based Compensation of $330000.0 for Q1 2026, down 43.69% year-over-year from $586000.0 in Q1 2025, and down 7.82% on a QoQ basis from $358000.0 in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Share-based Compensation data on file, last reported at $330000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 43.69% year-over-year to $330000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 42.11% YoY) and the FY2025 annual result came in at $2.1 million, down 44.32% from the prior year.
- Share-based Compensation declined to $330000.0 in Q1 2026 per CGTX's latest filing, from $358000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.2 million in Q1 2023 and bottomed at $330000.0 in Q1 2026.
- The 5-year median for Share-based Compensation is $896000.0 (2024), against an average of $828882.4.
- Peak annual rise in Share-based Compensation reached 979.17% in 2022, while the deepest fall reached 81.66% in 2022.
- Tracing CGTX's Share-based Compensation over 5 years: stood at $902000.0 in 2022, then gained by 18.74% to $1.1 million in 2023, then sank by 50.14% to $534000.0 in 2024, then slumped by 32.96% to $358000.0 in 2025, then decreased by 7.82% to $330000.0 in 2026.
- Per Business Quant, the three latest CGTX Share-based Compensation figures stand at $330000.0 (Q1 2026), $358000.0 (Q4 2025), and $522000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 257.40 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | 330,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 330,000.00 |
| Mar 31, 2026 | 330,000.00 |
| Dec 31, 2025 | 358,000.00 |
| Dec 31, 2025 | 358,000.00 |
| Sep 30, 2025 | 522,000.00 |
| Sep 30, 2025 | 522,000.00 |
| Jun 30, 2025 | 621,000.00 |
| Jun 30, 2025 | 621,000.00 |
| Mar 31, 2025 | 586,000.00 |
| Mar 31, 2025 | 586,000.00 |
| Dec 31, 2024 | 534,000.00 |
| Dec 31, 2024 | 534,000.00 |
| Sep 30, 2024 | 896,000.00 |
| Sep 30, 2024 | 896,000.00 |
| Jun 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.15 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Mar 31, 2024 | 1.17 Mn |
| Dec 31, 2023 | 1.07 Mn |
| Dec 31, 2023 | 1.07 Mn |
| Sep 30, 2023 | 1.07 Mn |
| Sep 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 1.03 Mn |
| Jun 30, 2023 | 1.03 Mn |
| Mar 31, 2023 | 1.19 Mn |
| Mar 31, 2023 | 1.19 Mn |
| Dec 31, 2022 | 902,000.00 |
| Dec 31, 2022 | 902,000.00 |
| Sep 30, 2022 | 777,000.00 |
| Sep 30, 2022 | 777,000.00 |
| Jun 30, 2022 | 892,000.00 |
| Jun 30, 2022 | 892,000.00 |
| Mar 31, 2022 | 1.00 Mn |
| Mar 31, 2022 | 1.00 Mn |
| Dec 31, 2021 | 4.92 Mn |
| Dec 31, 2021 | 4.92 Mn |
| Sep 30, 2021 | 72,000.00 |
| Sep 30, 2021 | 72,000.00 |
| Jun 30, 2021 | 94,000.00 |
| Jun 30, 2021 | 94,000.00 |
| Mar 31, 2021 | 98,000.00 |
| Mar 31, 2021 | 98,000.00 |
| Dec 31, 2020 | 133,000.00 |
| Dec 31, 2020 | 133,000.00 |
| Sep 30, 2020 | 129,000.00 |
| Sep 30, 2020 | 129,000.00 |